Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Neurocognitive Disorders

Ibogaine for Neurocognitive Disorders

4 papers and 1 clinical trial exploring ibogaine as a treatment for neurocognitive disorders.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
Indication55M+ people living with dementia worldwide

Neurocognitive Disorders

Neurocognitive disorders, including dementia, Alzheimer's disease, Parkinson's disease and traumatic brain injury, involve a progressive decline in memory, thinking and everyday function. Interest in psychedelics here rests on a strong biological rationale and early human safety signals, not on proven treatment: no completed controlled trial yet shows that psychedelics treat dementia or restore lost cognition.

Full Neurocognitive Disorders profile

Academic Research

4 papers
Open Accessindividual

Ibogaine for the treatment of Parkinson's disease: A case report

This case study (n=1) reports that an 80-day course of low-dose ibogaine hydrochloride in a woman with Parkinson's disease was followed by improvements in motor symptoms, quality of life, fatigue and depression, but worse sleep. No adverse events were recorded.

Published
January 6, 2026
Journal
Journal of Psychedelic Studies
Authors
Erny, T., Cano Montenegro, E. Y., Barth, J., Noller, G.
Paywallindividual

Predictors of psychedelic treatment outcomes among special operations forces veterans

This prospective study (n=86) examined the effects of ibogaine and 5-MeO-DMT treatment on U.S. Special Operations Forces Veterans with trauma exposure. Younger age and higher baseline levels of depression and anxiety were correlated with significant improvements in mental and psychosocial outcomes from baseline to 1-month follow-up. Greater intensity of changes in consciousness was linked to improved long-term mental health and psychosocial outcomes up to 6 months post-treatment.

Published
September 7, 2023
Journal
Psychology of Consciousness Theory Research and Practice
Authors
Xin, Y., Armstrong, S. B., Averill, L. A., Sepeda, N. D., Davis, A. K.
Open Accessindividual

Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

In a retrospective survey of 51 U.S. Special Operations Forces veterans who completed a psychedelic programme in Mexico (ibogaine and 5‑MeO‑DMT), participants reported very large reductions in suicidal ideation, PTSD, depression, anxiety and cognitive impairment alongside large increases in psychological flexibility. These preliminary, self‑reported findings are limited by retrospective design and lack of randomisation/blinding, so controlled trials are needed to establish efficacy.

Published
July 8, 2020
Journal
Chronic Stress
Authors
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., Amoroso, T.
Open Accessmeta

How toxic is ibogaine?

This systematic review (2016) investigated the pharmacological properties of ibogaine with special attention to its potential toxicity for human subjects. The authors found that evidence of toxicity exists, and suggest that certain factors like pre-existing cardiac conditions and concurrent medications may pose an additional risk.

Published
January 25, 2016
Journal
Clinical Toxicology
Authors
Litjens, R. P. W., Brunt, T. M.

Clinical Trials

1 trial
WithdrawnPhase II

Trifecta Research Study

Non-randomised, parallel interventional study (n=40) testing sequences of HRT, MeRT, ibogaine and 5‑MeO‑DMT in Special Operations Forces veterans with PTSD and cognitive difficulties following TBI.

Started
March 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06810765

Explore further

Search all Ibogaine papers Search all Neurocognitive Disorders trials Full Ibogaine profile Full Neurocognitive Disorders profile